Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
6 Jun 24
EFFECT
Notice of effectiveness
6 Jun 24
424B3
Prospectus supplement
5 Jun 24
S-3
Shelf registration
28 May 24
8-K
Nektar Therapeutics Reports First Quarter 2024 Financial Results
9 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Other Events
17 Apr 24
D
$30.00 mm in equity / options, sold $30.00 mm, 1 investor
19 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
4 Mar 24
8-K
Entry into a Material Definitive Agreement
4 Mar 24
8-K
Termination of a Material Definitive Agreement
16 Feb 24
8-K
Results of Operations and Financial Condition
10 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
7 Nov 23
8-K
Termination of a Material Definitive Agreement
8 Sep 23
S-8
Registration of securities for employees
11 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Nektar Therapeutics Reports Second Quarter 2023 Financial Results
8 Aug 23
8-K
Regulation FD Disclosure
7 Aug 23
8-K
Departure of Directors or Certain Officers
22 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Nektar Therapeutics Reports First Quarter 2023 Financial Results
9 May 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
8-K
Termination of a Material Definitive Agreement
27 Apr 23
8-K
Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan
17 Apr 23
8-K
Departure of Directors or Certain Officers
11 Apr 23
8-K
Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank
13 Mar 23
8-K
Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
28 Feb 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Regulation FD Disclosure
23 Feb 23
8-K
Results of Operations and Financial Condition
9 Jan 23
8-K
Other Events
22 Dec 22
8-K
Amendments to Articles of Incorporation or Bylaws
16 Dec 22
Latest ownership filings
4
ROBERT CHESS
14 Jun 24
144
Notice of proposed sale of securities
14 Jun 24
4
HOWARD W ROBIN
20 May 24
4
Jonathan Zalevsky
20 May 24
4
Mark Andrew Wilson
20 May 24
144
Notice of proposed sale of securities
17 May 24
144
Notice of proposed sale of securities
17 May 24
144
Notice of proposed sale of securities
17 May 24
4
DAVID KROIN
13 May 24
SC 13G
TCG Crossover GP II, LLC
15 Mar 24
3
DAVID KROIN
14 Mar 24
4
Jonathan Zalevsky
22 Feb 24
4
Mark Andrew Wilson
22 Feb 24
4
HOWARD W ROBIN
22 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
144
Notice of proposed sale of securities
20 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Jonathan Zalevsky
15 Dec 23
4
Mark Andrew Wilson
15 Dec 23
4
HOWARD W ROBIN
15 Dec 23
144
Notice of proposed sale of securities
15 Dec 23
4
Jonathan Zalevsky
20 Nov 23
4
Mark Andrew Wilson
20 Nov 23
4
HOWARD W ROBIN
20 Nov 23
144
Notice of proposed sale of securities
17 Nov 23
144
Notice of proposed sale of securities
17 Nov 23
144
Notice of proposed sale of securities
17 Nov 23
4
R SCOTT GREER
21 Sep 23
4
ROY A WHITFIELD
20 Sep 23
4
Myriam Curet
20 Sep 23
4
ROBERT CHESS
20 Sep 23
4
Diana Brainard
20 Sep 23
4
Jeffrey Robert Ajer
20 Sep 23
144
Notice of proposed sale of securities
18 Sep 23
4
Jonathan Zalevsky
17 Aug 23
4
Mark Andrew Wilson
17 Aug 23